Literature DB >> 20923603

An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease.

Fabio Blandini1.   

Abstract

The primary cause of the neurodegenerative process that underlies Parkinson's disease (PD) is still unknown. Different mechanisms probably contribute to triggering neuronal death in the nigrostriatal pathway, including mitochondrial defects, oxidative stress and proteolytic stress. Glutamate-mediated excitotoxicity may be a further contributor. Glutamate is the predominant fast excitatory neurotransmitter in the central nervous system and, in the presence of specific conditions, a potential neurotoxin. Although excitotoxicity per se is unlikely to act as a major causative agent in PD pathogenesis, glutamate-mediated intracellular changes may contribute, in a more subtle way, to the mechanisms that trigger the neurodegenerative process in the substantia nigra pars compacta (SNc). It is, therefore, likely that synergistic interactions between mitochondrial defects, oxidative stress and glutamatergic stimulation take place at the SNc level. These interactions may create the conditions for the development of the nigrostriatal damage that characterizes PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923603

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  41 in total

Review 1.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

2.  A neuroprotective role for microRNA miR-1000 mediated by limiting glutamate excitotoxicity.

Authors:  Pushpa Verma; George J Augustine; Mohamed-Raafet Ammar; Ayumu Tashiro; Stephen M Cohen
Journal:  Nat Neurosci       Date:  2015-02-02       Impact factor: 24.884

3.  Ion channels and ionotropic receptors in human embryonic stem cell derived neural progenitors.

Authors:  A Young; D W Machacek; S K Dhara; P R Macleish; M Benveniste; M C Dodla; C D Sturkie; S L Stice
Journal:  Neuroscience       Date:  2011-06-07       Impact factor: 3.590

4.  Ceftriaxone Protects Astrocytes from MPP(+) via Suppression of NF-κB/JNK/c-Jun Signaling.

Authors:  Yunlong Zhang; Xiuping Zhang; Shaogang Qu
Journal:  Mol Neurobiol       Date:  2014-08-12       Impact factor: 5.590

Review 5.  Kynurenines in Parkinson's disease: therapeutic perspectives.

Authors:  Dénes Zádori; Péter Klivényi; József Toldi; Ferenc Fülöp; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-08-20       Impact factor: 3.575

Review 6.  Neurodegeneration in the pathogenesis of diabetic retinopathy: molecular mechanisms and therapeutic implications.

Authors:  Maxwell S Stem; Thomas W Gardner
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 7.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 8.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

Review 9.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

10.  Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease.

Authors:  Ariana Q Farrand; Rebecca A Gregory; Cristina M Bäckman; Kristi L Helke; Heather A Boger
Journal:  Brain Res       Date:  2016-09-20       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.